Drug Approval | September 09, 2021
Merck’s KEYTRUDA receives China approval for Esophageal cancer
The medicine is now approved for eight indications across five different types of cancer in China.
The medicine is now approved for eight indications across five different types of cancer in China.
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
NUFYMCO BLA has been approved by the USFDA
The combination also outperformed chemotherapy on another important secondary endpoint
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Subscribe To Our Newsletter & Stay Updated
